SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics, Inc. (SABS) Healthcare & Pipeline Overview

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging its DiversitAb platform to develop fully human polyclonal antibody immunotherapies. Targeting infectious diseases like COVID-19 and influenza, as well as autoimmune disorders and cancer, SAB Biotherapeutics aims to provide novel treatments without relying on human donors, positioning itself in the competitive biotechnology landscape.

What Is the Investment Thesis for SABS?

SAB Biotherapeutics presents a notable research candidate within the biotechnology sector, driven by its innovative DiversitAb platform for producing fully human polyclonal antibodies. The Phase III clinical trial of SAB-185 for COVID-19 represents a near-term catalyst. Success in this trial could lead to regulatory approval and significant revenue generation. Further value drivers include the advancement of SAB-176 for influenza and SAB-142 for autoimmune diseases. However, the company faces risks inherent in clinical-stage drug development, including potential trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market cap of $37.28M and a P/E ratio of 5.5, SAB Biotherapeutics' valuation reflects both its potential and the associated risks. Successful execution of its clinical programs and strategic partnerships will be critical for realizing long-term value.

Based on FMP financials and quantitative analysis

SABS Key Highlights

• SAB-185 is in Phase III clinical trials for the treatment of COVID-19, representing a near-term potential revenue catalyst.
• DiversitAb platform offers a unique approach to producing fully human polyclonal antibodies without the need for human donors.
• SAB-176 is in development for the treatment or prevention of severe influenza, addressing a significant market need.
• Pre-clinical program SAB-142 targets autoimmune diseases like type 1 diabetes and organ transplant rejection, expanding the therapeutic pipeline.
• The company's market capitalization is $0.04 billion with a P/E ratio of 5.5, reflecting its growth potential and associated risks.

Who Are SABS's Competitors?

SABS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SABS's Key Strengths?

• Innovative DiversitAb platform for antibody production.
• Fully human polyclonal antibodies offer potential advantages over monoclonal antibodies.
• Lead product candidate SAB-185 in Phase III clinical trials.
• Experienced management team with expertise in antibody development.

What Are SABS's Weaknesses?

• Clinical-stage company with no currently approved products.
• Reliance on the success of clinical trials for future revenue.
• Limited financial resources compared to larger pharmaceutical companies.
• Potential for competition from established antibody therapeutics.

What Could Drive SABS Stock Higher?

• Data readout from the Phase III clinical trial of SAB-185 for COVID-19 in late 2026.
• Initiation of Phase II clinical trials for SAB-176 for influenza in 2027.
• Potential regulatory submissions for SAB-185 based on clinical trial results.
• Expansion of the DiversitAb platform to develop antibodies for new disease targets.
• Strategic partnerships and collaborations with pharmaceutical companies.

What Are the Key Risks for SABS?

• Financial-distress signal — its Altman Z-Score of 0.82 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-0.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for SAB-185 and other product candidates.
• Regulatory setbacks and challenges in obtaining marketing approval.
• Competition from established pharmaceutical companies and antibody therapeutics.
• Dependence on funding and capital markets to support research and development.
• Intellectual property challenges and patent disputes.

What Are the Growth Opportunities for SABS?

• Growth opportunity 1: Successful completion of the Phase III clinical trial for SAB-185 in COVID-19 could lead to Emergency Use Authorization (EUA) or full regulatory approval, potentially generating significant revenue. The global market for COVID-19 therapeutics remains substantial, with ongoing needs for effective treatments against emerging variants. Securing government contracts or partnerships with pharmaceutical companies could accelerate market penetration and commercial success. Timeline: Anticipated data readout and potential regulatory submissions in late 2026.
• Growth opportunity 2: Advancing SAB-176 for influenza represents a significant growth opportunity, addressing a large and recurring market. The global influenza therapeutics market is projected to reach billions of dollars annually, driven by the need for improved treatments against seasonal and pandemic influenza strains. Positive clinical trial results and strategic partnerships could position SAB-176 as a leading influenza therapeutic. Timeline: Phase II clinical trials anticipated to commence in 2027.
• Growth opportunity 3: Expansion of the pre-clinical program SAB-142 into clinical trials for type 1 diabetes and organ transplant rejection offers long-term growth potential. The market for autoimmune disease therapies is substantial and growing, driven by increasing prevalence and unmet medical needs. Successful development of SAB-142 could provide a novel treatment option for these conditions. Timeline: Phase I clinical trials anticipated to commence in 2028.
• Growth opportunity 4: Strategic partnerships with pharmaceutical companies or research institutions could accelerate the development and commercialization of SAB Biotherapeutics' pipeline. Collaborations could provide access to funding, expertise, and distribution channels, enhancing the company's competitive position. Identifying partners with complementary capabilities and shared strategic goals is crucial for maximizing the benefits of such alliances. Ongoing:
• Growth opportunity 5: Expanding the DiversitAb platform to develop antibodies for other infectious diseases and therapeutic areas represents a long-term growth opportunity. The platform's versatility allows for the rapid generation of fully human polyclonal antibodies against a wide range of targets. Identifying new disease targets and developing novel antibody therapeutics could drive future revenue growth and market expansion. Ongoing:

What Opportunities Does SABS Have?

• Successful completion of clinical trials and regulatory approval of SAB-185.
• Expansion of the DiversitAb platform to develop antibodies for other diseases.
• Strategic partnerships with pharmaceutical companies and research institutions.
• Government funding and grants for research and development.

What Threats Does SABS Face?

• Clinical trial failures and regulatory setbacks.
• Competition from established pharmaceutical companies.
• Changes in government regulations and healthcare policies.
• Economic downturn and reduced healthcare spending.

What Are SABS's Competitive Advantages?

• DiversitAb platform provides a unique and scalable source of fully human polyclonal antibodies.
• Intellectual property protection for the DiversitAb platform and antibody therapeutics.
• Established expertise in genetic engineering and antibody science.
• Potential for lower manufacturing costs compared to traditional antibody production methods.

What Does SABS Do?

Founded in 2014 and based in Sioux Falls, South Dakota, SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies. The company's core technology, the DiversitAb platform, utilizes advanced genetic engineering and antibody science to create transchromosomic bovine herds. These herds are engineered to produce fully human polyclonal antibodies targeted at a range of diseases. This approach eliminates the need for human donors, offering a scalable and consistent source of human antibodies. SAB Biotherapeutics' lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic currently in Phase III clinical trials for the treatment of COVID-19. Another key candidate is SAB-176, a fully-human polyclonal antibody therapeutic in development for the treatment or prevention of severe influenza. The company also has pre-clinical programs, including SAB-142, targeting autoimmune diseases such as type 1 diabetes and organ transplant induction/rejection. The company's focus on polyclonal antibodies provides a broader range of binding sites compared to monoclonal antibodies, potentially offering improved efficacy against evolving pathogens and complex diseases. SAB Biotherapeutics is dedicated to addressing unmet medical needs through its novel antibody platform.

What Products and Services Does SABS Offer?

• Develop immunotherapies based on fully human antibodies.
• Utilize genetically engineered bovine herds to produce human antibodies.
• Target infectious diseases, including COVID-19 and influenza.
• Develop treatments for immune and autoimmune disorders, such as type 1 diabetes.
• Create therapies for organ transplantation.
• Develop treatments for cancer.
• Use the DiversitAb immunotherapy platform to produce polyclonal antibodies.

How Does SABS Make Money?

• Develop and commercialize antibody-based therapeutics.
• Generate revenue through partnerships and collaborations.
• Out-licensing of technology and intellectual property.
• Government grants and funding for research and development.

What Industry Does SABS Operate In?

SAB Biotherapeutics operates within the competitive biotechnology industry, which is characterized by high R&D spending, regulatory scrutiny, and the potential for significant returns on successful drug development. The market for antibody therapeutics is experiencing substantial growth, driven by advancements in genetic engineering and immunology. SAB Biotherapeutics' DiversitAb platform positions it to capitalize on this trend by offering a novel approach to antibody production. Competition includes established pharmaceutical companies and other biotechnology firms developing antibody-based therapies.

Who Are SABS's Key Customers?

• Patients suffering from infectious diseases like COVID-19 and influenza.
• Individuals with autoimmune disorders, such as type 1 diabetes.
• Organ transplant recipients.
• Cancer patients.

ROE -0%Key Financial Metrics

Return on equity for SAB Biotherapeutics, Inc. stands at -0.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.2%, showing how much profit it generates from its asset base. A current ratio of 11.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.2%, the inverse of the P/E and a quick read on earnings relative to price.

How SAB Biotherapeutics, Inc. Is Valued

SAB Biotherapeutics, Inc. carries a market capitalization of $37.28M, placing it in the micro-cap category. Relative to its peer group, SABS's quantitative score of 44/100 is below the peer average of 76/100.

F-Score 1/9Financial Health

SAB Biotherapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.82 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project SAB Biotherapeutics, Inc. revenue of about $333K for fiscal 2026, with EPS near $-1.05. The estimate reflects 5 contributing analysts.

SABS Financials

SABS Latest News

SABS Analyst Consensus

SABS MoonshotScore

SAB Biotherapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources